In the neoadjuvant setting, physicians treating resectable pancreatic cancer have more treatment options than ever before. Recently, however, the routine use of radiotherapy has been called into question, leading to a debate at the 5th Annual School of Gastrointestinal Oncology™ (SOGO®), hosted by Physicians’ Education Resource, LLC®.
Susan Tsai, MD, MSH, an Associate Professor at the Medical College of Wisconsin in Milwaukee, argued in favor of neoadjuvant strategies for treating pancreatic cancer that routinely use radiotherapy. Her opponent, Michael Choti, MD, MBA, chief of surgery at Banner MD Anderson Cancer Center in Phoenix, Arizona, who argued against the use of always using radiotherapy in the in resectable patient, rather favoring neoadjuvant chemotherapy in all patients prior to surgical treatment, and only using radiation therapy selectively for borderline and locally advanced tumors. Read more . . .